Clinical Trial Protocol
Iranian Registry of Clinical Trials

15 Nov 2026

In- Vivo Bioequivalence study of Rizatriptan tablet 10 mg Mofid Pharma with brand drugs (MAXALT® 10 mg, Merck Sharp & Dohme, MSD, Germany) in Iranian healthy volunteers.

Protocol summary

Study aim
In- Vivo Bioequivalence study of Pirfenidone tablet 200 mg Arang Pharma with brand drug (PIRFENEX® 200mg, Cipla, India) in Iranian healthy volunteers.

Design
In-vivo bioequivalence study of Rizatriptan tablet 10 mg Mofid Pharma in comparison with reference drug (MAXALT® 10 mg, Merck Sharp & Dohme, MSD, Germany). The single blind, Cross-over, two period, two groups (Intervention and control) and randomized (paper lottery randomization method) study with one week wash-out time.

Settings and conduct
This study is carried out in Simin Baspar Tayf-Gostar Company, Tabriz, Iran. The study population is 24 healthy Iranian volunteers.This study is a single blind study and by taking out the drugs from the existing packaging, the volunteers will not know the time of receiving the test drug and the brand. This study is a cross over study that is performed in two time periods of 72 hours with a two-week wash-out period.

Participants/Inclusion and exclusion criteria
Inclusion criteria: age between 18-60 years old; body mass index (BMI) in the range of 18-28. Exclusion criteria: history of heart, kidney and liver disease; pregnancy; drug addiction.

Intervention groups
Single dose Rizatriptan tablet 10 mg Mofid Pharma. Control group: Single dose MAXALT® 10 mg, Merck Sharp & Dohme, MSD, Germany

Main outcome variables
Plasma drug concentration

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20200105046010N62**
Registration date: **2022-06-25, 1401/04/04**
Registration timing: **registered_while_recruiting**

Last update: **2022-06-25, 1401/04/04**
Update count: **0**

Registration date
2022-06-25, 1401/04/04

Registrant information

Name
Javad Shokri

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 41 3661 4125

Email address
shokri.j@gmail.com

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2022-06-15, 1401/03/25

Expected recruitment end date
2023-01-15, 1401/10/25

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
In- Vivo Bioequivalence study of Rizatriptan tablet 10 mg Mofid Pharma with brand drugs (MAXALT® 10 mg, Merck

Sharp & Dohme, MSD, Germany) in Iranian healthy volunteers.

Public title
In-vivo Bioequivalence Test ofRizatriptan tablet 10 mg Mofid Pharma with brand drug (MAXALT® 10 mg, Merck Sharp & Dohme, MSD, Germany)
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
General health Body mass index between18-28 Informed consent Being at the age of 18-60 years old
Exclusion criteria:
Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug
Age
From **18 years** old to **60 years** old
Gender
Both

Phase
Bioequivalence
Groups that have been masked

- Participant

Sample size
Target sample size: **24**
Randomization (investigator's opinion)
Randomized
Randomization description
For this purpose, A 24- persons group will be selected and divided to two 12-persons groups randomly. The names of all volunteers will be written on paper pieces and wrapped in aluminum foils. The first 12 papers will randomly be withdrawn from bottle will be selected as group A and others will be categorized in group B.
Blinding (investigator's opinion)
Single blinded
Blinding description
Candidates are not aware of receiving the test drug or brand one. In a single study, information that could distort the test result is hidden from the candidates, but the person in charge of the test is aware of it. Test and Brand drugs are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test drug.
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Tabriz University of Medical Sciences
Street address
Third floor; Central building; Tabriz University of Medical Sciences; Dneshgah St.
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Approval date
2021-08-02, 1400/05/11
Ethics committee reference number
IR.TBZMED.REC.1400.467

Health conditions studied

1

Description of health condition studied
Bio equivalence test
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Plasma drug concentration
Timepoint
Sampling times in this study will be 0، 0.5، 1، 1.25، 1.5، 1.75، 2، 2.5، 3، 3.5، 4، 6، 10 .8، 12، 24 hours after prescribing the tablet.
Method of measurement
High Performance Liquid Chromatography with tandem mass spectroscopy detector

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: One test tablet (Rizatriptan tablet 10 mg Mofid Pharma) will be received. Blood samples will be taken for 24 hours at the mentioned times after drug administration and the concentration of the drug in Plasma samples will be measured by liquid chromatography with mass spectroscopy detector
Category
Treatment - Other

2

Description
Control group: One Reference tablet MAXALT 10 mg, Merck Sharp & Dohme, MSD, Germany will be received. Blood samples will be taken for 24 hours at the mentioned times after drug administration and the concentration of drug in plasma samples will be measured by liquid chromatography with mass spectroscopy detector.
Category
Treatment - Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Simin Baspar Teyf Gostar Company
Full name of responsible person
Javad Shokri
Street address
No.48, Ferdos square
City
Tabriz
Province
East Azarbaijan
Postal code
5167874434
Phone
+98 41 3384 2724
Email
Shokri.j@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Teb Mofid Nikan Pharmaceutical Co.
Full name of responsible person
Mohammad Reza Zargarzadeh
Street address
Tehran Shahid Beheshti Street Ahmad Qusayr Street, Pazhouheshgah(2) alley, fifth floor
City
Tehran
Province
Tehran
Postal code
3361658369
Phone
+98 21 8817 5119
Fax
+98 26 4422 8116
Email
info@mofidpharma.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Teb Mofid Nikan Pharmaceutical Co.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Persons

Person responsible for general inquiries

Contact
Name of organization / entity
Simin Baspar Teyf Gostar Company
Full name of responsible person
Dariush Omidfar
Position
Lab. Manager
Latest degree
Master
Other areas of specialty/work
Bioanalysis
Street address
No.48, Ferdos square
City
Tabriz
Province
East Azarbaijan
Postal code
5167874434
Phone
+98 41 3384 2724
Email
Dariush.omidfar@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Javad Shokri
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Daneshgah
City
Tabriz
Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3334 8489

Email

Shokri.j@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Simin Baspar Teyf Gostar Company

Full name of responsible person

Ahad Sheikhloo

Position

Official Manager

Latest degree

Master

Other areas of specialty/work

Biochemistry

Street address

No.48, Ferdos square

City

Tabriz

Province

East Azarbaijan

Postal code

5167874434

Phone

+98 41 3384 2724

Email

ahad.sheikhloo@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

All information and data of the study will remain secured based on the agreement established between researcher and drug producer.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available